Patient description: The patient is a 35-year-old woman with myasthenia gravis, class IIa. She complains of diplopia and fatigue and weakness that affects mainly her upper limbs. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She takes pyridostigmine 60 mg three times a day. But she still has some symptoms that interfere with her job. She is a research coordinator and has 3 children. Her 70-year-old father has hypertension. She does not smoke or use illicit drugs. She drinks alcohol occasionally at social events. Her physical exam and lab studies were not remarkable for any other abnormalities. BP: 110/75 Hgb: 11 g/dl WBC: 8000 /mm3 Plt: 300000 /ml Creatinine: 0.5 mg/dl BUN: 10 mg/dl Beta hcg: negative for pregnancy

Clinical trial eligibility criteria: eligible ages (years): 19.0-999.0,  Sickle Cell Disease Recipient Age greater than or equal to 19 years Diagnosis of sickle cell disease (HB SS, SC, or SBeta-thal(0)); confirmed by hemoglobin electrophoresis, high-performance liquid chromatography, DNA testing when necessary or both At high risk for disease-related morbidity or mortality, defined by having at least one of the following manifestations (A-E) A: Clinically significant neurologic event (stroke) or any neurological deficit lasting > 24 hours B: History of two or more episodes of acute chest syndrome (ACS) in the 2-year period preceding enrollment despite the institution of supportive care measures including hydroxyurea C: Three or more pain crises per year in the 2-year period preceding referral (required intravenous pain management in the outpatient or inpatient hospital setting) despite the institution of supportive care measures including hydroxyurea D: Administration of regular RBC transfusion therapy, defined as receiving 8 or more transfusions per year for ≥ 1 year to prevent vaso-occlusive clinical complications (i.e. pain, stroke, acute chest syndrome, and priapism) E: Pulmonary hypertension (defined as tricuspid regurgitant jet velocity (TRV) ≥2.5 m/s at baseline (without vaso-occlusive crisis) Any one of the below complications not ameliorated by hydroxyurea at the maximum tolerated dose for at least 6 months  Detectable antibody to ABO, Rh, or other red blood cell antigen of their donors Presence of donor specific antibodies detected by donor specific antibody screen (if using product from a haploidentical donor) Karnofsky/Lansky performance score < 60 Evidence of uncontrolled bacterial, viral, or fungal infections (currently taking medication and progression of clinical symptoms) within one month prior to starting the conditioning regimen. Patients with fever or suspected minor infection should await resolution of symptoms before starting the conditioning regimen Poor cardiac function defined as left ventricular ejection fraction < 40% Poor pulmonary function defined as FEV1 and FVC < 40% predicted or diffusing capacity of the lung for carbon monoxide (DLCO) < 40% (corrected for hemoglobin) Poor liver function defined as direct bilirubin > 2x upper limit of normal for age and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) > 5 times upper limit of normal Poor kidney function defined by creatinine clearance < 70mL/min HIV-positive Unwillingness to use approved contraception method from time of biologic assignment until discontinuation of all immunosuppressive medications